• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Relationship between Atherogenic Dyslipidemia and Target Lesion Revascularization Post Everolimus-Eluting Stent Implantation.

作者信息

Nozue Tsuyoshi

机构信息

Division of Cardiology, Department of Internal Medicine, Yokohama Sakae Kyosai Hospital.

出版信息

J Atheroscler Thromb. 2023 Dec 1;30(12):1761-1762. doi: 10.5551/jat.ED239. Epub 2023 Aug 8.

DOI:10.5551/jat.ED239
PMID:37558460
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10703548/
Abstract
摘要

相似文献

1
Relationship between Atherogenic Dyslipidemia and Target Lesion Revascularization Post Everolimus-Eluting Stent Implantation.依维莫司洗脱支架植入术后致动脉粥样硬化性血脂异常与靶病变血运重建的关系。
J Atheroscler Thromb. 2023 Dec 1;30(12):1761-1762. doi: 10.5551/jat.ED239. Epub 2023 Aug 8.
2
Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).在冠状动脉疾病中，依维莫司洗脱支架与紫杉醇洗脱支架的荟萃分析：SPIRIT 临床试验计划的最终 3 年结果（在治疗新发病变的患者中，使用依维莫司洗脱冠状动脉支架系统治疗的西里斯 V 依维莫司洗脱冠状动脉支架系统的临床评估）。
JACC Cardiovasc Interv. 2013 Sep;6(9):914-22. doi: 10.1016/j.jcin.2013.05.005.
3
Three-Year Clinical Outcomes With the Cilotax Dual Drug-Eluting Stent vs Everolimus-Eluting Stents in Patients With Acute Myocardial Infarction.急性心肌梗死患者中 Cilotax 双药物洗脱支架与依维莫司洗脱支架的 3 年临床结果。
Tex Heart Inst J. 2024 May 1;51(1). doi: 10.14503/THIJ-23-8271.
4
Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds.依维莫司洗脱冠状动脉支架与依维莫司洗脱生物可吸收血管支架的比较。
J Am Coll Cardiol. 2015 Mar 3;65(8):791-801. doi: 10.1016/j.jacc.2014.12.017.
5
Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable-Polymer Everolimus-Eluting Stent for Percutaneous Coronary Revascularization: 2-Year Results of the BIOSCIENCE Trial.用于经皮冠状动脉血运重建的超薄支柱可生物降解聚合物西罗莫司洗脱支架与耐用聚合物依维莫司洗脱支架对比：BIOSCIENCE试验的2年结果
J Am Heart Assoc. 2016 Mar 15;5(3):e003255. doi: 10.1161/JAHA.116.003255.
6
Deteriorative Effect of a Combination of Hypertriglyceridemia and Low High-Density Lipoprotein Cholesterolemia on Target Lesion Revascularization after Everolimus-Eluting Stent Implantation.高甘油三酯血症和低高密度脂蛋白胆固醇血症联合对依维莫司洗脱支架置入后靶病变血运重建的恶化影响。
J Atheroscler Thromb. 2023 Dec 1;30(12):1778-1790. doi: 10.5551/jat.64010. Epub 2023 Apr 25.
7
Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization: 3-Year Outcomes From the Randomized BIOFLOW V Trial.超薄生物可吸收聚合物西罗莫司洗脱支架与薄型持久聚合物依维莫司洗脱支架在冠状动脉血运重建中的比较：随机 BIOFLOW V 试验 3 年结果。
JACC Cardiovasc Interv. 2020 Jun 8;13(11):1343-1353. doi: 10.1016/j.jcin.2020.02.019.
8
Impact of Coronary Calcification on Clinical Outcomes After Implantation of Newer-Generation Drug-Eluting Stents.新型药物洗脱支架植入术后冠状动脉钙化对临床结局的影响。
J Am Heart Assoc. 2021 Jun 15;10(12):e019815. doi: 10.1161/JAHA.120.019815. Epub 2021 May 29.
9
Biodegradable-Polymer Biolimus-Eluting Stents versus Durable-Polymer Everolimus-Eluting Stents at One-Year Follow-Up: A Registry-Based Cohort Study.一年随访期内生物可降解聚合物生物雷帕霉素洗脱支架与耐用聚合物依维莫司洗脱支架的比较：一项基于注册登记的队列研究。
Tex Heart Inst J. 2016 Apr 1;43(2):126-30. doi: 10.14503/THIJ-14-4997. eCollection 2016 Apr.
10
3-Year Clinical Follow-Up of the RIBS IV Clinical Trial: A Prospective Randomized Study of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis in Coronary Arteries Previously Treated With Drug-Eluting Stents.3 年 RIBS IV 临床试验临床随访：药物洗脱球囊与依维莫司洗脱支架治疗药物洗脱支架治疗后冠状动脉支架内再狭窄患者的前瞻性随机研究。
JACC Cardiovasc Interv. 2018 May 28;11(10):981-991. doi: 10.1016/j.jcin.2018.02.037.

引用本文的文献

1
Percutaneous transluminal angioplasty with stenting for the treatment of lower limb arteriosclerosis obliterans.经皮腔内血管成形术联合支架置入治疗下肢动脉硬化闭塞症。
Wideochir Inne Tech Maloinwazyjne. 2024 Nov 28;19(4):465-469. doi: 10.20452/wiitm.2024.17915. eCollection 2024 Dec 27.

本文引用的文献

1
Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022.日本动脉粥样硬化协会（JAS）2022年动脉粥样硬化性心血管疾病预防指南。
J Atheroscler Thromb. 2024 Jun 1;31(6):641-853. doi: 10.5551/jat.GL2022. Epub 2023 Dec 19.
2
Deteriorative Effect of a Combination of Hypertriglyceridemia and Low High-Density Lipoprotein Cholesterolemia on Target Lesion Revascularization after Everolimus-Eluting Stent Implantation.高甘油三酯血症和低高密度脂蛋白胆固醇血症联合对依维莫司洗脱支架置入后靶病变血运重建的恶化影响。
J Atheroscler Thromb. 2023 Dec 1;30(12):1778-1790. doi: 10.5551/jat.64010. Epub 2023 Apr 25.
3
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.用佩马弗他酯降低甘油三酯以降低心血管风险。
N Engl J Med. 2022 Nov 24;387(21):1923-1934. doi: 10.1056/NEJMoa2210645. Epub 2022 Nov 5.
4
Impact of triglyceride levels on plaque characteristics in patients with coronary artery disease.甘油三酯水平对冠心病患者斑块特征的影响。
Int J Cardiol. 2022 Feb 1;348:134-139. doi: 10.1016/j.ijcard.2021.12.008. Epub 2021 Dec 9.
5
Highly Selective PPARα (Peroxisome Proliferator-Activated Receptor α) Agonist Pemafibrate Inhibits Stent Inflammation and Restenosis Assessed by Multimodality Molecular-Microstructural Imaging.高选择性过氧化物酶体增殖物激活受体 α（PPARα）激动剂 pemafibrate 通过多模态分子-微观结构成像评估抑制支架炎症和再狭窄。
J Am Heart Assoc. 2021 Oct 19;10(20):e020834. doi: 10.1161/JAHA.121.020834. Epub 2021 Oct 11.
6
Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials.降脂治疗与多种降脂治疗类别降低心血管风险的关联：一项随机对照试验的系统评价和荟萃回归分析。
Circulation. 2019 Oct 15;140(16):1308-1317. doi: 10.1161/CIRCULATIONAHA.119.041998. Epub 2019 Sep 18.
7
Difference of Tissue Characteristics Between Early and Late Restenosis After Second-Generation Drug-Eluting Stents Implantation　- An Optical Coherence Tomography Study.第二代药物洗脱支架植入术后早期和晚期再狭窄组织特征的差异——光学相干断层扫描研究
Circ J. 2017 Mar 24;81(4):450-457. doi: 10.1253/circj.CJ-16-1069. Epub 2017 Jan 27.
8
Postprandial Hyperlipidemia and Remnant Lipoproteins.餐后高脂血症与残留脂蛋白
J Atheroscler Thromb. 2017 Feb 1;24(2):95-109. doi: 10.5551/jat.RV16003. Epub 2016 Nov 8.
9
Non-HDL Cholesterol and Triglycerides: Implications for Coronary Atheroma Progression and Clinical Events.非高密度脂蛋白胆固醇与甘油三酯：对冠状动脉粥样硬化进展及临床事件的影响
Arterioscler Thromb Vasc Biol. 2016 Nov;36(11):2220-2228. doi: 10.1161/ATVBAHA.116.307601. Epub 2016 Aug 11.
10
Effects of combination lipid therapy in type 2 diabetes mellitus.2 型糖尿病的联合降脂治疗效果。
N Engl J Med. 2010 Apr 29;362(17):1563-74. doi: 10.1056/NEJMoa1001282. Epub 2010 Mar 14.